Salnavac®

Intranasal form of a combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus. The vaccine is based on an adenoviral vector with a fragment of SARS-COV-2 genetic built-in material, encoding information about the structure of the S-protein of the virus spike (the protein responsible for its binding to human cells). The fragment of genetic material itself is safe for human, but the drug causes activation of systemic humoral and cellular immunity and forms mucosal immune protection on the surface of the mucous membrane of the respiratory tract against infection with coronavirus infection caused by the SARS-CoV-2 virus.